Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NVET (NVET) (NVET) Stock Price, News & Analysis Add Share Share Stock Analysis Stock Analysis About (NVET) Stock (NASDAQ:NVET) 30 days 90 days 365 days Advanced Chart Ad Colonial MetalsA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get (NVET) alerts:Sign Up Key Stats Today's Range$6.72▼$6.7250-Day Range N/A52-Week Range$2.75▼$6.76VolumeN/AAverage Volume38,104 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company’s advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).Read More… A “Thank You Gift” From Pres. Trump - Genius (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Receive NVET Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (NVET) and its competitors with MarketBeat's FREE daily newsletter. Email Address NVET Stock News HeadlinesMavericks' forgotten bench player is missing piece in playoff puzzleApril 23, 2024 | msn.com‘A man who understands Hong Kong’: Beijing’s new liaison office head vows to bridge communication between city and central authoritiesJanuary 16, 2023 | msn.comBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.November 24, 2024 | Brownstone Research (Ad)Prescott has 2 TD passes, Cowboys top banged-up Titans 27-13December 30, 2022 | msn.comSelena Gomez Talks Mental Health in ‘My Mind and Me’ TrailerOctober 10, 2022 | msn.comCOVID in California: Boston sees a ‘worrisome’ virus spike in wastewaterSeptember 29, 2022 | msn.com"There was a lot of screaming, it was terrifying": City centre workers' fears as man stabbed outside Mile Castle pub in NewcastleAugust 18, 2022 | msn.comNymox Pharmaceutical Corporation NewsJuly 1, 2022 | thestreet.comSee More Headlines NVET Stock Analysis - Frequently Asked Questions How were (NVET)'s earnings last quarter? (NVET) (NASDAQ:NVET) issued its quarterly earnings results on Thursday, May, 11th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.02. When did (NVET) IPO? (NVET) (NVET) raised $58 million in an initial public offering on Thursday, February 5th 2015. The company issued 4,000,000 shares at $13.00-$16.00 per share. BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Piper Jaffray and JMP Securities were co-managers. What other stocks do shareholders of (NVET) own? Based on aggregate information from My MarketBeat watchlists, some other companies that (NVET) investors own include Frontline (FRO), Achillion Pharmaceuticals (ACHN), Anthera Pharmaceuticals (ANTH), Sphere 3D (ANY), Arena Pharmaceuticals (ARNA), Yamana Gold (AUY) and BioLineRx (BLRX). Company Calendar Last Earnings5/11/2017Today11/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:NVET CUSIPN/A CIK1618561 Webwww.nexvet.com Phone+353-1-2158100FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:NVET) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could...Investors Alley | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (NVET) Please log in to your account or sign up in order to add this asset to your watchlist. Share (NVET) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.